Last reviewed · How we verify
NCT04125186
A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US
trial testing Baseline EpiNP survey in Nocturnal Polyuria in 10,190 participants. Completed in 30 June 2020.
30 June 2020
Quick facts
| Lead sponsor | Ferring Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10,190 |
| Start date | 22 July 2019 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Baseline EpiNP survey
- Bladder diary
- Testing of EpiNP baseline survey, bladder diary and a qualitative interview
- No other intervention
Conditions studied
- Nocturnal Polyuria — all drugs for Nocturnal Polyuria →
Sponsor
Ferring Pharmaceuticals — full company profile →
Who can join
30 and older, any sex, with Nocturnal Polyuria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To estimate the prevalence of nocturia due to nocturnal polyuria (NP) in the US and describe the demographic and clinical characteristics as well as the burden of illness in participants with nocturia due to NP.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Prevalence of Nocturnal Polyuria in the United States: Results from the Epidemiology of Nocturnal Polyuria Study.
Weiss JP, Bosch JLHR, Chapple CR, Bacci ED, et al · · 2022 · cited 8× · PMID 35039242 · DOI 10.1016/j.euf.2021.12.016 -
Differences in the Prevalence of Nocturnal Polyuria in the U.S. by Definition: Results from the Epidemiology of Nocturnal Polyuria Study.
Bosch JLHR, Chapple CR, Mueller ER, Rosenberg MT, et al · · 2022 · cited 2× · PMID 35446110 · DOI 10.1097/ju.0000000000002500
Verify or expand the search:
- PubMed search for NCT04125186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ferring Pharmaceuticals trials
Trials by the same sponsor.
- NCT07152730 — A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump · Phase 1 · withdrawn
- NCT07029451 — To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt · recruiting
- NCT06668493 — Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis · Phase 1, PHASE2 · recruiting
- NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
- NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04125186 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ferring Pharmaceuticals
- Last refreshed: 13 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing